TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03477435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training and academic detailing
Description: Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training and academic detailing
Description: Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
Study: NCT00653640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: body weight supported treadmill training
Description: BWSTT for 12 weeks, 3 times per week

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy
Description: traditional PT for 12 weeks, 3 times per week
Study: NCT00725296

Intervention type: BIOLOGICAL
Intervention: Remicade (Infliximab)
Description: Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
Study: NCT01031810

Intervention type: DRUG
Group type: OTHER
Intervention: tranylcypromine
Description: MAO-Inhibitor 60mg-120mg
Study: NCT01456026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycated beta-lactoglobulins.
Description: oral, 20 g, single administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-glycated beta-lactoglobulins
Description: 20 g, oral, single administration,
Study: NCT01083251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon + Vitamin D
Description: 180 mcg/week + 400 IUX2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon
Description: 180 mcg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sebivo
Description: Telbivudine 600 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir+ vitamin d
Description: entecavir 1 mg daily+ vitamin d
Study: NCT04290156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint visits
Description: The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
Study: NCT02932488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
Study: NCT03651154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypovolemic Phlebotomy
Description: Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
Study: NCT01906216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study: NCT03066648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
Study: NCT02109718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Dressings with Petrolatum Jelly
Description: participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine Gauze Dressing Group
Description: Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
Study: NCT03066648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
Study: NCT04798911

Intervention type: OTHER
Intervention: Phase 1 Observational Interviews
Description: Qualitative interviews with patients with SS

Intervention type: OTHER
Intervention: Phase 1 Observational Interviews
Description: Qualitative interviews with patients with SS
Study: NCT03966417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Continuous exercise training 2 times per week for a period of 12 weeks.
Study: NCT01896128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive pill manufactured to mimic Armodafinil 150 mg tablet
Study: NCT01809054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arixtra

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic compression stockings
Description: Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT02050906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral activity counseling
Description: Undergo behavioral activity and nutritional counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone based counseling
Description: Undergo behavioral activity and nutritional counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03003533

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8011
Description: A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8011
Description: A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8011
Description: A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8011
Description: A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
Study: NCT01356875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIDRA/VPA
Description: In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
Study: NCT02611466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Study: NCT03812913

Intervention type: BEHAVIORAL
Intervention: psychological evaluation
Description: * Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning.

Intervention type: BEHAVIORAL
Intervention: psychological evaluation
Description: * Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning.
Study: NCT01538550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Description: Flexible sigmoidoscopy screening is offered once only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iFOBT
Description: Biennial screening with iFOBT
Study: NCT02415933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trickle Up
Description: Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trickle Up Plus
Description: In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage).
Study: NCT01294358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
Study: NCT03613454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic coils
Description: Splenic artery embolization with vascular embolic coils
Study: NCT01809054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT00570856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo similar to the folic acid tablets, 1/day
Study: NCT03565211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
Study: NCT03811197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling via face to face meeting
Description: All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling via face to face meeting
Description: All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling via face to face meeting
Description: All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Suggestions
Description: All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B).
Study: NCT03742674

Intervention type: OTHER
Intervention: Follow up
Description: No intervention
Study: NCT01475188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergovit
Description: commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
Study: NCT00510549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modality: Peritoneal Dialysis
Description: Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modality: Peritoneal Dialysis
Description: Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
Study: NCT03945565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
Study: NCT04430270

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Sequential Assignment
Study: NCT03563950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days
Study: NCT03613454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splenic artery embolization with vascular embolic plugs
Description: Splenic artery embolization with vascular embolic plugs
Study: NCT01511744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza split vaccine
Description: 3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
Study: NCT05774418

Intervention type: BIOLOGICAL
Intervention: BNT162b2 COVID-19 Vaccine
Description: BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
Study: NCT00005615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: Interferon alfa as outlined in treatment arm.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy as outlined in treatment arm.
Study: NCT03232528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion
Description: Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham herb-partitioned moxibustion
Description: Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.